Itradoc 200 Capsule contains Itraconazole 200 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various systemic and superficial fungal infections caused by susceptible fungi, including dermatophytes, yeasts, and molds. Itraconazole acts by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for ergosterol synthesis, a key component of fungal cell membranes. This inhibition disrupts membrane integrity, leading to fungal cell death. Itradoc 200 is commonly prescribed for conditions such as onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and candidiasis. The capsule formulation ensures optimal bioavailability and patient compliance. Dosage should be individualized based on the severity and type of infection, with treatment duration varying accordingly. It is recommended to administer Itradoc with food to enhance absorption. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions should be reviewed due to itraconazole’s effect on cytochrome P450 enzymes. Adverse effects may include gastrointestinal disturbances, headache, rash, and elevated liver enzymes. Regular monitoring of liver function tests is recommended during prolonged therapy. Itradoc 200 Capsule should be used under strict medical supervision to ensure efficacy and safety.